Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LIPA | P38571 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.31 |
| ▸ | SHBG | P04278 | 2/20 | 0.31 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8484507 | 0.98 | NR1I3 (0.38) | NR1I3TSHRLIPAGAALMNA | |
| SCHEMBL8484503 | 0.98 | NR1I3 (0.38) | NR1I3TSHRLIPAGAALMNA | |
| SCHEMBL8488656 | 0.90 | TSHR (0.33) | NR1I3TSHRLMNAGPBAR1SHBG | |
| SCHEMBL8488657 | 0.90 | TSHR (0.33) | NR1I3TSHRLMNAGPBAR1SHBG | |
| SCHEMBL9815688 | 0.87 | NR1I3 (0.40) | NR1I3TSHRLMNAGPBAR1SHBG | |
| SCHEMBL497942 | 0.87 | — | — | |
| SCHEMBL7132308 | 0.78 | LIPA (0.40) | TSHRLIPAGAALMNAHSD17B10 | |
| SCHEMBL2568051 | 0.78 | LIPA (0.40) | TSHRLIPAGAALMNAHSD17B10 | |
| SCHEMBL15261953 | 0.78 | LIPA (0.40) | TSHRLIPAGAALMNAHSD17B10 | |
| SCHEMBL497572 | 0.78 | LIPA (0.40) | TSHRLIPAGAALMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863571-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | Shering Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060281778-A1 | Compounds for inhibiting KSP Kinesin activity | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| WO-2006098962-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281778-A1 | Compounds for inhibiting KSP Kinesin activity | KIFC1, KIF5B, KIF2C | NR1I3 2144/4885TSHR 4460/4885LIPA 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.